Advances in clustered regularly interspaced short palindromic repeat (CRISPR) and their associated protein (Cas9)-based epigenetic editing, combined with small molecule inhibitors like EZH2 or HDAC inhibitors, allow precise gene and epigenetic regulation, offering the potential for cancer and genetic disorder treatments. This evidence concerns the gene EZH2 and cancer.